secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuBase Therapeutics, Inc. (—)
CIK:        0001173281
Form:       8-K
Filed at:   2024-01-17T23:59:59+00:00
Accession:  0001104659-24-004247
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NeuBase terminates CEO Dietrich Stephan; appoints CFO Todd Branning as interim CEO
--------------------------------------------------------------------------------

- Board terminated Dietrich A. Stephan as CEO without cause, effective Jan 16, 2024.
- Todd P. Branning, CFO since Jan 2022, appointed interim CEO, retaining CFO role.
- Dr. Stephan expected to continue serving on the Board.
- Branning's compensation unchanged as a result of the appointment.
- No family relationships or material transactions with Branning disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173281/000110465924004247/0001104659-24-004247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173281/000110465924004247/tm243413d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-004247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer